MediWound (MediWound) NonCurrent Deferred Liabilities : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is MediWound NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

MediWound's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $0.00 Mil.

MediWound NonCurrent Deferred Liabilities Historical Data

The historical data trend for MediWound's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediWound NonCurrent Deferred Liabilities Chart

MediWound Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

1.14

1.23

0.12

MediWound Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

MediWound NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of MediWound's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

MediWound (MediWound) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediWound Ltd (NAS:MDWD) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

M8W:Germany

Address

42 Hayarkon Street, Yavne, ISR, 8122745

Website

https://www.mediwound.com

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from the United States.